LRRK2 and Parkinson disease: However, a recent Phase-1 clinical study with an inhibitor (DNL201) that suppressed LRRK2 pathway activity by ~70%, concluded that this compound was safe and well tolerated, warranting further clinical development of LRRK2 inhibitors as a therapeutic modality for PD (Jennings et al, 2022).